| Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery Y Zou, J Xie, S Zheng, W Liu, Y Tang, W Tian, X Deng, L Wu, Y Zhang, ... International Journal of Surgery 107, 106936, 2022 | 246 | 2022 |
| The single‐cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer Y Zou, F Ye, Y Kong, X Hu, X Deng, J Xie, C Song, X Ou, S Wu, L Wu, ... Advanced Science 10 (5), 2203699, 2023 | 174 | 2023 |
| N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer Y Zou, S Zheng, X Xie, F Ye, X Hu, Z Tian, SM Yan, L Yang, Y Kong, ... Nature communications 13 (1), 2672, 2022 | 151 | 2022 |
| Dissection of FOXO1-induced LYPLAL1-DT impeding triple-negative breast cancer progression via mediating hnRNPK/β-catenin complex Y Tang, W Tian, S Zheng, Y Zou, J Xie, J Zhang, X Li, Y Sun, J Lan, N Li, ... Research 6, 0289, 2023 | 91 | 2023 |
| Prognosis and dissection of immunosuppressive microenvironment in breast cancer based on fatty acid metabolism-related signature Y Tang, W Tian, J Xie, Y Zou, Z Wang, N Li, Y Zeng, L Wu, Y Zhang, S Wu, ... Frontiers in immunology 13, 843515, 2022 | 74 | 2022 |
| Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer S Zheng, Y Zou, Y Tang, A Yang, JY Liang, L Wu, W Tian, W Xiao, X Xie, ... Oncoimmunology 11 (1), 2020984, 2022 | 70 | 2022 |
| Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer X Ou, Y Tan, J Xie, J Yuan, X Deng, R Shao, C Song, X Cao, X Xie, R He, ... Drug Resistance Updates 73, 101063, 2024 | 68 | 2024 |
| Advances in artificial intelligence to predict cancer immunotherapy efficacy J Xie, X Luo, X Deng, Y Tang, W Tian, H Cheng, J Zhang, Y Zou, Z Guo, ... Frontiers in immunology 13, 1076883, 2023 | 54 | 2023 |
| Circular RNA: a promising new star of vaccine J Xie, F Ye, X Deng, Y Tang, JY Liang, X Huang, Y Sun, H Tang, J Lei, ... Journal of translational internal medicine 11 (4), 372-381, 2023 | 41 | 2023 |
| The pan-cancer multi-omics landscape of FOXO family relevant to clinical outcome and drug resistance J Xie, J Zhang, W Tian, Y Zou, Y Tang, S Zheng, CW Wong, X Deng, S Wu, ... International Journal of Molecular Sciences 23 (24), 15647, 2022 | 40 | 2022 |
| Establishment of a cell necroptosis index to predict prognosis and drug sensitivity for patients with triple-negative breast cancer J Xie, W Tian, Y Tang, Y Zou, S Zheng, L Wu, Y Zeng, S Wu, X Xie, X Xie Frontiers in Molecular Biosciences 9, 834593, 2022 | 39 | 2022 |
| Dissecting the role of cancer‐associated fibroblast‐derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single‐cell transcriptomic … S Zheng, JY Liang, Y Tang, J Xie, Y Zou, A Yang, N Shao, X Kuang, F Ji, ... Clinical and translational medicine 13 (2), e1189, 2023 | 34 | 2023 |
| Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC J Xie, S Zheng, Y Zou, Y Tang, W Tian, CW Wong, S Wu, X Ou, W Zhao, ... Frontiers in immunology 13, 1022147, 2022 | 34 | 2022 |
| Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies J Xie, M Liu, X Deng, Y Tang, S Zheng, X Ou, H Tang, X Xie, M Wu, Y Zou Imeta 3 (1), e156, 2024 | 30 | 2024 |
| Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer J Xie, X Deng, Y Xie, H Zhu, P Liu, W Deng, L Ning, Y Tang, Y Sun, ... MedComm 5 (3), e502, 2024 | 29 | 2024 |
| A novel platelet-related gene signature for predicting the prognosis of triple-negative breast cancer J Xie, Y Zou, F Ye, W Zhao, X Xie, X Ou, X Xie, W Wei Frontiers in cell and developmental biology 9, 795600, 2022 | 28 | 2022 |
| Recent advances in exosome-based immunotherapy applied to cancer J Xie, Z Zheng, L Tuo, X Deng, H Tang, C Peng, Y Zou Frontiers in immunology 14, 1296857, 2023 | 27 | 2023 |
| Development and verification of a prognostic ferroptosis-related gene model in triple-negative breast cancer S Wu, R Pan, J Lu, X Wu, J Xie, H Tang, X Li Frontiers in Oncology 12, 896927, 2022 | 27 | 2022 |
| Tumor-derived exosomal ENO2 modulates polarization of tumor-associated macrophages through reprogramming glycolysis to promote progression of diffuse large B-cell lymphoma R Shao, C Liu, R Xue, X Deng, L Liu, C Song, J Xie, H Tang, W Liu International journal of biological sciences 20 (3), 848, 2024 | 26 | 2024 |
| Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer J Xie, Y Zou, T Gao, L Xie, D Tan, X Xie Cancer control 29, 10732748221099230, 2022 | 19 | 2022 |
Xinpei DengSun Yat-sen University Cancer centerEmail yang diverifikasi di sysucc.org.cn